Compounds for treating muscular dystrophy

A method for the therapeutic or prophylactic treatment of (a) when X is N, Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia, or (b) when X is CRx, Duchenne muscular dystrophy or Becker muscular dystrophy, comprising administering a compound of formula (I):

• or a tautomer, enantiomer, pharmaceutically acceptable salt, hydrate, solvate, complex, or prodrug thereof, wherein
• X is CRx or N;
• Rx is H or C1-C6 alkyl;
• L1 is a bond, —(CR5R5)n—, —NR5—, —O—, —S—, —(CR5R5)nNR5—, —C(O)NR5—, —C(O)NR5O—, —C(S)NR5—, —NR5C(O)—, —NR5C(S)—, —NR5C(NH)—, —SO2NR5—, —NR5SO2—, —C(O)—, —C(S)—, —SO—, —SO2—, —CR5═CR5—, —C≡C—, —NR5C(O)NR5—, —NR5C(S)NR5—, —NR5C(NH)NR5—, —NR5C(O)O—, or —OC(O)NR5—;
• R1 is C1-C10 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with one or more ORS, N(R5)2, R6, or OR6;
• or
• R1 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system;
• L2 is —(CR5R5)n—, —(CR5R5)nO—, —C(O)—, —C(NR5)—, —SO2—, —C(O)NR5—, or —SO2NR5—;
• R2 is C1-C10 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, each of which is optionally substituted with optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system;
• or
• R2 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system;
• Each of R3 and R4 is independently hydrogen, C1-C6 alkyl, OH, —O(C1-C6 alkyl), halo, SOmR5, or NR5R5;
• or
• R3 and R4 together with the carbon atoms to which they are attached form a 5-6 membered aromatic or 5-7 membered non-aromatic carbocyclic or heterocyclic ring system, each of which is optionally substituted with one or more C1-C6 alkyl, OH, —O(C1-C6 alkyl), halo, SOmR5, C(O)R5, or NR5R5;
• m is 0, 1, or 2;
• n is 1 or 2;
• each R5 is independently H or C1-C6 alkyl optionally substituted with one or more halo;
• and
• R6 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system.